Table 2.
Description of MM subgroups.
| MGUS | SCT w/o IT | SCT with IT * | MM Progressed | No SCT, IT or Other Therapy | Total n | |
|---|---|---|---|---|---|---|
| Group number | G 1 | G 2 | G 3 | G 4 | G 5 | |
| n per group | 7 | 11 | 12 | 12 | 4 | 46 |
| SCT | 0 | 11 | 12 | 10 | 0 | 33 |
| >2 y since SCT at inclusion | 9 | 8 | 6 | 23 | ||
| >2 y since SCT at 6 mo after vd3 | 10 | 10 | 10 | 30 | ||
| Treatment in G4 (MM Progressed) | No SCT + dara mono | SCT + dara or + dara & dexa |
SCT + dara (of double or triple) | No SCT + PI | SCT + PI | |
| n per group | 1 | 5 | 4 | 1 | 1 | 12 |
Abbreviations: dara, Daratumumab; dexa, Dexamethasone; IT, immunomodulatory treatment; MGUS, monoclonal gammopathy of undetermined significance; MM, multiple myeloma; mo, months; n. a., not applicable; PI, proteasome inhibitor; SCT, stem cell transplant;vd, vaccine dose; y, years. * IT: lenalidomid and/or pomalidomid and/or dexamethasone.